The GLP-1 landscape is complex and rapidly evolving. Omada is expanding our integrated platform to better navigate the complexities of the GLP-1 landscape. The three new initiatives include:
Omada will launch prescribing capabilities starting with GLP-1s and other obesity medications, integrating evidence-based prescribing with proven lifestyle support
Omada’s GLP-1 Flex Care gives employers a way to support employee access to branded GLP-1s for obesity through established cash-pay channels
Omada for Cholesterol delivers between-visit support for the many adults whose LDL remains uncontrolled under usual care, bringing dedicated cholesterol management into our integrated model
Omada leads through compassionate intelligence—using AI to complement our human-led care teams and extend virtual-first care between visits.
Learn more about how we are expanding care and coverage across our cardiometabolic platform here.